Ankylosing Spondylitis News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Study Launched to Assess Impact of Higher Dose of Cosentyx in Patients with AS - Ankylosing Spondylitis News



Ankylosing Spondylitis News
 
Study Launched to Assess Impact of Higher Dose of Cosentyx in Patients with AS 
Ankylosing Spondylitis News
Novartis has initiated a Phase 4 clinical trial to evaluate the impact of increasing the dose of Cosentyx (secukinumab) to 300 mg. in patients with ankylosing spondylitis (AS) who did not achieve symptom remission after 16 weeks of treatment with 150 ...

 


Ankylosing spondylitis disease activity, transfusion associated with blood loss during THA - Healio



Ankylosing spondylitis disease activity, transfusion associated with blood loss during THA 
Healio
Results of this retrospective study showed a positive association between disease activity, allogeneic blood transfusion volume and change of hematocrit concentration from preoperatively to postoperatively with perioperative blood loss among patients ...

 


Withdrawing Therapy in Patients With Arthritis - Medscape



Medscape
 
Withdrawing Therapy in Patients With Arthritis 
Medscape
Hello. I'm Dr Jonathan Kay, professor of medicine and the Timothy S. and Elaine L. Peterson Chair in Rheumatology at the University of Massachusetts Medical School and UMass Memorial Medical Center, both in Worcester, Massachusetts. I'm here in San ...

 


Ankylosing Spondylitis (Bekhterev's Disease) Pipeline Analysis 2017 - Insider Tradings



Insider Tradings
 
Ankylosing Spondylitis (Bekhterev's Disease) Pipeline Analysis 2017 
Insider Tradings
Ankylosing Spondylitis (Bekhterev's Disease)-Mechanism of action Insights, 2017?, report provides comprehensive insights of the ongoing therapeutic research and development across Ankylosing Spondylitis (Bekhterev's Disease). The report provides a ...

and more » 


Novartis Initiates Study Evaluating Impact of Higher Dosing of Cosentyx in Patients with Ankylosing Spondylitis - Drug Discovery & Development



Drug Discovery & Development
 
Novartis Initiates Study Evaluating Impact of Higher Dosing of Cosentyx in Patients with Ankylosing Spondylitis 
Drug Discovery & Development
Novartis announced the initiation of the ASLeap trial in patients with ankylosing spondylitis (AS), evaluating the effect of changing to a higher dose (300 mg) of Cosentyx (secukinumab) in patients who do not achieve symptom remission after treatment ...

 


Novartis initiates study evaluating impact of higher dosing of Cosentyx® in patients with ankylosing spondylitis - Markets Insider



Novartis initiates study evaluating impact of higher dosing of Cosentyx® in patients with ankylosing spondylitis 
Markets Insider
EAST HANOVER, N.J., Dec. 7, 2017 /PRNewswire/ -- Novartis announced today the initiation of the ASLeap trial in patients with ankylosing spondylitis (AS), evaluating the effect of changing to a higher dose (300 mg) of Cosentyx® (secukinumab) in ...
Novartis launches study evaluating higher dose of Cosentyx in patients with ankylosing spondylitis Seeking Alpha

all 2 news articles » 


TNF Inhibitors Decrease Extraarticular Manifestations in Ankylosing Spondylitis - Rheumatology Advisor



Rheumatology Advisor
 
TNF Inhibitors Decrease Extraarticular Manifestations in Ankylosing Spondylitis 
Rheumatology Advisor
SAN DIEGO ? Tumor necrosis factor (TNF) inhibitors were shown to reduce the incidence and prevalence of comorbidities and extraarticular manifestations among patients with ankylosing spondylitis, according to research to be presented at the American ...

 


Nearly a Fifth of IBD Patients Have a Joint Condition, Veterans Study in Texas Indicates - Ankylosing Spondylitis News



Ankylosing Spondylitis News
 
Nearly a Fifth of IBD Patients Have a Joint Condition, Veterans Study in Texas Indicates 
Ankylosing Spondylitis News
But IBD patients can have joint conditions as well. Spondyloarthritis is a broad term for inflammatory diseases of joints and the ligaments and tendons attached to bone. The most common spondyloarthritis condition is ankylosing spondylitis, which ...

 


US Market Report for Ankylosing Spondylitis Immunology Drugs 2018 - MedCore - PR Newswire (press release)



US Market Report for Ankylosing Spondylitis Immunology Drugs 2018 - MedCore 
PR Newswire (press release)
Another option includes biologics, such as HUMIRA® (adalimumab), Amjevita? and Imraldi® (biosimilars to HUMIRA®), CIMZIA® (certolizumab pegol), Enbrel® (etanercept), Erelzi® and Benepali® (biosimilars to Enbrel®), SIMPONI® (golimumab), REMICADE ...

and more » 


Pioneering spinal surgery changes Middletown man's life - WCPO



WCPO
 
Pioneering spinal surgery changes Middletown man's life 
WCPO
Doctors diagnosed him with ankylosing spondylitis and set him up with Botox injections to relax his strained muscles, but long-term solutions weren't forthcoming. "Neurosurgeons wouldn't touch me," he said. "I had one doctor tell me I was going to live ...

and more »